× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy


× Important note: This Web site presents preliminary results. We are working non-stop to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 2

Bivalirudin

colchicine

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs

sodium aescinate

Apilimod

corticosteroids 5

ciclesonide

dexamethasone 1

inhaled steroids

low-dose corticosteroids

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

rhG-CSF

vaccines

Immunosuppressants drugs

anakinra

eculizumab

interleukin-6 inhibitor

clazakizumab

sarilumab

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 1

azvudine

baloxavir marboxil

carrimycin

chloroquine and derivatives 4

chloroquine 1

hydroxychloroquine 11

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

hydroxychloroquine plus macrolides 4

interferon

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 3

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

meplazumab

oseltamivir plus chloroquin

remdesevir 2

Renin-angiotensin-system-acting agents 6

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 1

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

enoxaparin

levamisole

natural killer (NK) cells

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

prone positioning

PUL-042 inhalation solution

selinexor

stem cells

tradipitant

tranilast

Latest studies

lopinavir/ritonavir vs. standard of care some concern in risk of bias

    preliminary results given by the way of a press release.

  • inconclusive results for: mortality

preliminary results given by the way of a press release.

meta-analysis

Lagier , 2020   OBS 7 days ago

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • suggested 70 % decrease in death, ICU transfer, hospitalization ≥ 10 days but with a very low degree of certainty due to critical risk of bias
  • suggested 51 % decrease in mortality but with a very low degree of certainty due to critical risk of bias
  • suggested 62 % decrease in hospitalization ≥ 10 days but with a very low degree of certainty due to critical risk of bias

meta-analysis

Sbidian (HCQ alone) , 2020   OBS 2 weeks ago

hydroxychloroquine vs. control critical risk of bias

  • inconclusive results for: 28-day mortality

meta-analysis

hydroxychloroquine plus macrolides vs. control critical risk of bias

  • inconclusive results for: 28-day mortality

meta-analysis

RECOVERY dexamethasone unpublished   NCT04381936 2 weeks ago

dexamethasone vs. standard of care NA risk of bias

  • demonstrated 17 % decrease in death

in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)

meta-analysis

RECOVERY unpublished   NCT04381936 4 weeks ago

hydroxychloroquine vs. control NA risk of bias

  • inconclusive results for: 28-day death

meta-analysis

Boulware , 2020   NCT04308668 4 weeks ago

hydroxychloroquine vs. placebo low risk of bias

  • inconclusive results for: death; incidence of new illness compatible with Covid-19; hospitalization

meta-analysis

NIH NIAID ACTT-1 , 2020   NCT04280705 2 months ago

remdesevir vs. placebo some concern in risk of bias

  • suggested 32 % increase in recovery
  • suggested 28 % decrease in serious adverse events
  • inconclusive results for: death

meta-analysis

Rosenberg , 2020   OBS 2 months ago

hydroxychloroquine vs. control serious risk of bias

  • safety concerns with a 91 % increase in cardiac arrest
  • inconclusive results for: in hospital mortality; Abnormal ECG findings; Arrhythmia

meta-analysis

Rosenberg , 2020   OBS 2 months ago

azithromycin vs. control serious risk of bias

  • inconclusive results for: in hospital mortality; cardiac arrest; Abnormal ECG findings; Arrhythmia

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons